key: cord-0821771-t1z84ile authors: Chang, Yoon-Seok title: The way we communicate in allergy date: 2020-10-30 journal: Asia Pac Allergy DOI: 10.5415/apallergy.2020.10.e45 sha: f6e5f1bd737d516d274a6bdf0bcc796754c9038f doc_id: 821771 cord_uid: t1z84ile nan Recently Japanese Society of Allergology/World Allergy Organization (WAO) Joint Congress in conjunction with Asia Pacific Academy of Pediatric Allergy, Respirology and Immunology was successfully held virtually from September 17 to October 20, 2020 with more than 5,500 participants. It was just like a luxury buffet with excellent lectures, and the feast lasted for a month. The 15th World Immune Regulatory Meeting lasts from June 30, 2020 to July 3, 2021! In the new normal era, coronavirus disease 2019 (COVID-19) has changed the way we communicate in the academic and scientific world. Last month, I could invite 400 families for an annual event on atopic dermatitis instead of 50 families because it was virtually held. Hope Asia Pacific Allergy can play an important role as the way we communicate in allergy even in the era of COVID-19. Drug allergy/hypersensitivity is a frequent type of adverse events in hospitals [1] . The challenges in the diagnosis and management of drug allergy/hypersensitivity could be different in Asia from non-Asian countries. This issue features a very unique and important report on the diagnostic procedures and practices in drug allergy/hypersensitivity from 15 member societies of Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) [2] . It is very meaningful that it is the first survey on drug allergy/hypersensitivity from APAAACI Drug Allergy Committee and that the previous WAO International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity was published almost a decade ago [3] . This issue also contains a review article on the clinical value of in vitro tests for the management of severe drug hypersensitivity reactions from a Thai group sharing their experience [4] . Dias de Castro et al. [5] report the psychological profiles of patients with suspected drug allergy in Portugal. Anaphylaxis is an acute generalized life-threatening allergic reaction. In 1913, Charles Richet was awarded the Nobel Prize in Physiology or Medicine for his researches on anaphylaxis. This issue contains very interesting case reports: A pediatric anaphylaxis caused by gummy tablets containing fish collagen from Japan [6] , and the first case report of anaphylaxis after ingestion of Liparis tanakae from Korea [7] . 'Epinephrine' is the drug of choice in anaphylaxis. However, the physicians' awareness on the diagnosis of anaphylaxis and the epinephrine use still needs to be improved as Pimentel-Hayashi et al. [8] reported in this issue. It is also important to educate 119 or 911 rescue team or school nurses, and to improve their awareness Characteristics associated with the occurrence of adverse events: a retrospective medical record review using the Global Trigger Tool in a fully digitalized tertiary teaching hospital in Korea Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions Psychological profiles of patients with suspected drug allergy A case of pediatric anaphylaxis caused by gummy tablets containing fish collagen A case of anaphylaxis after ingestion of Liparis tanakae Physicians' knowledge regarding epinephrine underuse in anaphylaxis 119 Rescue team's awareness of anaphylaxis and asthma exacerbation in Gyeonggi-do province of Korea: before and after education Feasibility of a 3-step protocol of wheat oral immunotherapy in children with severe wheat allergy CD11c(+) dendritic cells coexpressing thymic stromal lymphopoietin receptor in animal model of eosinophilic otitis media Atypical presentation of Good syndrome: acute hepatitis from hepatitis B virus reactivation World Allergy Organization; c2020